{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:15:20Z","timestamp":1790082920843,"version":"4.0.1"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.blre.2023.101095","type":"journal-article","created":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T09:46:05Z","timestamp":1682761565000},"page":"101095","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need"],"prefix":"10.1016","volume":"60","author":[{"given":"Yasmine","family":"St. Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph K.","family":"Franz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounzer E.","family":"Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillard M.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2023.101095_bb0005","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global manufacturing of CAR T cell therapy","volume":"4","author":"Levine","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.blre.2023.101095_bb0010","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.imlet.2019.10.014","article-title":"CART manufacturing process and reasons for academy-pharma collaboration","volume":"217","author":"Egri","year":"2020","journal-title":"Immunol Lett"},{"issue":"11","key":"10.1016\/j.blre.2023.101095_bb0015","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1016\/j.bbmt.2019.06.036","article-title":"Understanding and managing large B cell lymphoma relapses after chimeric antigen receptor T cell therapy","volume":"25","author":"Byrne","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"10.1016\/j.blre.2023.101095_bb0020","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.blre.2023.101095_bb0025","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.blre.2023.101095_bb0030","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2006","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2023.101095_bb0035","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.blre.2023.101095_bb0040","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2021","journal-title":"N Engl J Med"},{"issue":"10343","key":"10.1016\/j.blre.2023.101095_bb0045","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.blre.2023.101095_bb0050","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.blre.2023.101095_bb0055","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.blre.2023.101095_bb0060","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"27","key":"10.1016\/j.blre.2023.101095_bb0065","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: Outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.blre.2023.101095_bb0070","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: Results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.blre.2023.101095_bb0075","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1002\/cam4.3881","article-title":"Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma","volume":"10","author":"Iacoboni","year":"2021","journal-title":"Cancer Med"},{"issue":"16","key":"10.1016\/j.blre.2023.101095_bb0080","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum Interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"355","key":"10.1016\/j.blre.2023.101095_bb0085","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin&#x2019;s lymphoma with a defined ratio of CD8<sup>+<\/sup> and CD4<sup>+<\/sup> CD19-specific chimeric antigen receptor&#x2013;modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"issue":"13","key":"10.1016\/j.blre.2023.101095_bb0090","first-page":"1832","article-title":"Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy","volume":"137","author":"Spiegel","year":"2021","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.blre.2023.101095_bb0095","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1182\/blood.2022016945","article-title":"Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: A DESCAR-T analysis","volume":"140","author":"Di Blasi","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2023.101095_bb0100","doi-asserted-by":"crossref","first-page":"E209","DOI":"10.1002\/ajh.25505","article-title":"Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy","volume":"94","author":"Chow","year":"2019","journal-title":"Am J Hematol"},{"issue":"16","key":"10.1016\/j.blre.2023.101095_bb0105","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2023.101095_bb0110","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2023.101095_bb0115","doi-asserted-by":"crossref","first-page":"927153","DOI":"10.3389\/fimmu.2022.927153","article-title":"CAR-T cell therapy in hematological malignancies: Current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"issue":"7750","key":"10.1016\/j.blre.2023.101095_bb0120","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.blre.2023.101095_bb0125","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/cas.14799","article-title":"Preclinical and clinical advances in dual-target chimeric antigen receptor therapy for hematological malignancies","volume":"112","author":"Guo","year":"2021","journal-title":"Cancer Sci"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101095_bb0130","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1182\/blood-2018-99-115319","article-title":"Clinical predictors of T cell fitness for CAR T cell manufacturing and efficacy in multiple myeloma","volume":"132","author":"Dancy","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101095_bb0135","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.humpath.2016.03.005","article-title":"Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas","volume":"54","author":"Menter","year":"2016","journal-title":"Hum Pathol"},{"issue":"21","key":"10.1016\/j.blre.2023.101095_bb0140","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1182\/blood-2018-10-879015","article-title":"PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell\u2013inflamed phenotype","volume":"133","author":"Godfrey","year":"2019","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.blre.2023.101095_bb0145","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma","volume":"126","author":"Kiyasu","year":"2015","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.blre.2023.101095_bb0150","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.blre.2023.101095_bb0155","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/blood.V128.22.183.183","article-title":"A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039)","volume":"128","author":"Ansell","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2023.101095_bb0160","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.blre.2023.101095_bb0165","doi-asserted-by":"crossref","first-page":"10541","DOI":"10.1038\/s41598-017-10940-8","article-title":"Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment","volume":"7","author":"Yeku","year":"2017","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.blre.2023.101095_bb0170","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.blre.2023.101095_bb0175","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"26","key":"10.1016\/j.blre.2023.101095_bb0180","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101095_bb0185","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/blood-2018-99-112572","article-title":"Checkpoint inhibitors augment CD19-directed chimeric antigen receptor (CAR) T cell therapy in relapsed B-cell acute lymphoblastic leukemia","volume":"132","author":"Li","year":"2018","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101095_bb0190","first-page":"578","article-title":"Long-term follow-up ZUMA-1: A pivotal trial of axicabtagene ciloleucel (Axi-Cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL)","volume":"130","author":"Neelapu","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2023.101095_bb0195","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood.2021012634","article-title":"Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy","volume":"139","author":"Chong","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101095_bb0200","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1182\/blood-2022-157829","article-title":"Poor survival outcomes of checkpoint inhibitors for B-cell lymphomas relapsing after or refractory to CAR T-cell therapy: A real-world cohort from 15 U.S. academic institutions","volume":"140","author":"Major","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101095_bb0205","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2023010016","article-title":"Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: Outcomes from 15 U.S. institutions","author":"Major","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.blre.2023.101095_bb0210","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/cei.13407","article-title":"TIGIT as an emerging immune checkpoint","volume":"200","author":"Harjunp\u00e4\u00e4","year":"2020","journal-title":"Clin Exp Immunol"},{"issue":"8","key":"10.1016\/j.blre.2023.101095_bb0215","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1158\/2159-8290.CD-21-1586","article-title":"Sequential single-cell transcriptional and protein marker profiling reveals TIGIT as a marker of CD19 CAR-T cell dysfunction in patients with non-Hodgkin lymphoma","volume":"12","author":"Jackson","year":"2022","journal-title":"Cancer Discov"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101095_bb0220","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2020-133820","article-title":"Subcutaneous epcoritamab induces complete responses with an encouraging safety profile across relapsed\/refractory B-cell non-Hodgkin lymphoma subtypes, including patients with prior CAR-T therapy: Updated dose escalation data","volume":"136","author":"Hutchings","year":"2020","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2023.101095_bb0225","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/hon.2858","article-title":"Bispecific antibodies for the treatment of lymphomas: Promises and challenges","volume":"39","author":"Schuster","year":"2021","journal-title":"Hematol Oncol"},{"issue":"10306","key":"10.1016\/j.blre.2023.101095_bb0230","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: An open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"issue":"Supplement_1","key":"10.1016\/j.blre.2023.101095_bb0235","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-123742","article-title":"Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, Including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines","volume":"134","author":"Schuster","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2023.101095_bb0240","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): Results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101095_bb0245","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2022-158406","article-title":"Odronextamab in patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL): Results from a Prespecified analysis of the pivotal phase II study ELM-2","volume":"140","author":"Kim","year":"2022","journal-title":"Blood"},{"issue":"287","key":"10.1016\/j.blre.2023.101095_bb0250","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3 T cell&#x2013;dependent bispecific antibody for the treatment of B cell malignancies","volume":"7","author":"Sun","year":"2015","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.blre.2023.101095_bb0255","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: Phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101095_bb0260","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1182\/blood-2022-157729","article-title":"Subcutaneous mosunetuzumab is active with a manageable safety profile in patients (pts) with relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphomas (B-NHLs): Updated results from a phase I\/II study","volume":"140","author":"Budde","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2023.101095_bb0265","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14102516","article-title":"Glofitamab treatment in relapsed or refractory DLBCL after CAR T-cell therapy","volume":"14","author":"Rentsch","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"24","key":"10.1016\/j.blre.2023.101095_bb0270","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101095_bb0275","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2022-157554","article-title":"Relapse is uncommon in patients with large B-cell lymphoma who are in complete remission at the end of fixed-course glofitamab treatment","volume":"140","author":"Hutchings","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101095_bb0280","doi-asserted-by":"crossref","first-page":"9443","DOI":"10.1182\/blood-2022-158245","article-title":"Epcoritamab monotherapy provides deep and durable responses including minimal residual disease (MRD) negativity: Novel subgroup analyses in patients with relapsed\/refractory (R\/R) large B-cell lymphoma (LBCL)","volume":"140","author":"Phillips","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101095_bb0285","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1182\/blood-2022-166385","article-title":"Interim results of the phase 1 study of Tnb-486, a novel CD19xCD3 T-cell engager, in patients with relapsed\/refractory (R\/R) B-NHL","volume":"140","author":"Hou","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101095_bb0290","doi-asserted-by":"crossref","first-page":"9461","DOI":"10.1182\/blood-2022-157011","article-title":"CD19 4-1BBL (RO7227166) a novel costimulatory bispecific antibody can be safely combined with the T-cell-engaging bispecific antibody glofitamab in relapsed or refractory B-cell non-Hodgkin lymphoma","volume":"140","author":"Hutchings","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2023.101095_bb0295","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1182\/bloodadvances.2021006801","article-title":"A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy","volume":"6","author":"Gouni","year":"2022","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101095_bb0300","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1182\/blood-2022-159594","article-title":"Mosunetuzumab with polatuzumab vedotin is effective and has a manageable safety profile in patients aged <65 and \u226565 years with relapsed\/refractory diffuse large B-Cell lymphoma (R\/R DLBCL) and \u22651 prior therapy: Subgroup analysis of a phase Ib\/II study","volume":"140","author":"Olszewski","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2023.101095_bb0305","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","article-title":"ADCT-402, a PBD dimer\u2013containing antibody drug conjugate targeting CD19-expressing malignancies","volume":"131","author":"Zammarchi","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2023.101095_bb0310","doi-asserted-by":"crossref","first-page":"10479","DOI":"10.1038\/s41598-018-28533-4","article-title":"Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine","volume":"8","author":"Hartley","year":"2018","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.blre.2023.101095_bb0315","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): A multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101095_bb0320","doi-asserted-by":"crossref","first-page":"12079","DOI":"10.1182\/blood-2022-163277","article-title":"A phase 1b open-label study of loncastuximab tesirine in combination with other anticancer agents in patients with relapsed or refractory (R\/R) B-cell non-Hodgkin lymphoma (LOTIS-7)","volume":"140","author":"Hess","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2023.101095_bb0325","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/bjh.17460","article-title":"The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy","volume":"193","author":"Dholaria","year":"2021","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2023.101095_bb0330","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jtct.2022.10.026","article-title":"Allogeneic hematopoietic cell transplantation after chimeric antigen receptor T cell therapy in large B cell lymphoma","volume":"29","author":"Fried","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.blre.2023.101095_bb0335","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3324\/haematol.2022.281242","article-title":"Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma","volume":"108","author":"Zurko","year":"2023","journal-title":"Haematologica"},{"issue":"17","key":"10.1016\/j.blre.2023.101095_bb0340","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1182\/blood.2020009432","article-title":"CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma","volume":"137","author":"Baird","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101095_bb0345","doi-asserted-by":"crossref","first-page":"12716","DOI":"10.1182\/blood-2022-162604","article-title":"CRC-403: a phase 1\/2 study of bbT369, a dual CD79a and CD20 targeting CAR T cell drug product with a gene edit, in relapsed and\/or refractory B cell non-Hodgkin's lymphoma (NHL)","volume":"140","author":"Locke","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101095_bb0350","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1182\/blood-2022-157400","article-title":"A phase 1 study of ADI-001: anti-CD20 CAR-engineered allogeneic gamma Delta1 (\u03b3\u03b4) T cells in adults with B-cell malignancies","volume":"140","author":"Neelapu","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2023.101095_bb0355","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","article-title":"Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: An analysis of the European Group for Blood and Marrow Transplantation Registry","volume":"29","author":"Kampen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101095_bb0360","author":"National Center Institute: Surveillance, Epidemiology, and End Results Program"},{"key":"10.1016\/j.blre.2023.101095_bb0365","doi-asserted-by":"crossref","first-page":"100929","DOI":"10.1016\/j.blre.2022.100929","article-title":"Current state and next-generation CAR-T cells in multiple myeloma","volume":"54","author":"Manier","year":"2022","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2023.101095_bb0370","doi-asserted-by":"crossref","first-page":"991092","DOI":"10.3389\/fimmu.2022.991092","article-title":"Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma","volume":"13","author":"Chekol Abebe","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.blre.2023.101095_bb0375","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.clml.2022.09.001","article-title":"Recent advances in the use of chimeric antigen receptor-expressing T-cell therapies for treatment of multiple myeloma","volume":"23","author":"Martin","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"10.1016\/j.blre.2023.101095_bb0380","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"10297","key":"10.1016\/j.blre.2023.101095_bb0385","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2023.101095_bb0390","first-page":"JCO2200842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","author":"Martin","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101095_bb0395","doi-asserted-by":"crossref","first-page":"720571","DOI":"10.3389\/fimmu.2021.720571","article-title":"Efficacy of humanized anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma patients with and without extramedullary disease","volume":"12","author":"Deng","year":"2021","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.blre.2023.101095_bb0400","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.2022017848","article-title":"Interventions and outcomes of multiple myeloma patients receiving salvage treatment after BCMA-directed CAR T therapy","volume":"141","author":"Van Oekelen","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101095_bb0405","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/blood-2022-160401","article-title":"Clinical outcomes and salvage therapies in patients with relapsed\/refractory multiple myeloma following progression on BCMA-targeted CAR-T therapy","volume":"140","author":"Reyes","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2023.101095_bb0410","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1158\/2643-3230.BCD-20-0227","article-title":"Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma","volume":"2","author":"van de Donk","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"6","key":"10.1016\/j.blre.2023.101095_bb0415","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"10.1016\/j.blre.2023.101095_bb0420","doi-asserted-by":"crossref","first-page":"8007","DOI":"10.1200\/JCO.2022.40.16_suppl.8007","article-title":"Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1","volume":"40","author":"Nooka","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101095_bb0425","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood-2022-162440","article-title":"Efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma na\u00efve to B-cell maturation antigen (BCMA)-directed therapies: Results from cohort a of the Magnetismm-3 study","volume":"140","author":"Bahlis","year":"2022","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.blre.2023.101095_bb0430","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.blre.2023.101095_bb0435","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101095_bb0440","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1182\/blood-2022-162395","volume":"140","author":"Bal","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101095_bb0445","doi-asserted-by":"crossref","first-page":"780442","DOI":"10.3389\/fimmu.2021.780442","article-title":"T cell fitness and autologous CAR T cell therapy in haematologic malignancy","volume":"12","author":"Mehta","year":"2021","journal-title":"Front Immunol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101095_bb0450","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): Updated results from an ongoing phase I study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101095_bb0455","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2022-157547","article-title":"Enduring responses after 1-year, fixed-duration cevostamab therapy in patients with relapsed\/refractory multiple myeloma: Early experience from a phase I study","volume":"140","author":"Lesokhin","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101095_bb0460","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1182\/blood-2022-162253","article-title":"Final results from the first-in-human phase 1\/2 study of Modakafusp alfa, an immune-targeting attenuated cytokine, in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"140","author":"Vogl","year":"2022","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:31:15Z","timestamp":1759437075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X23000565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":92,"alternative-id":["S0268960X23000565"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2023.101095","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2023.101095","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101095"}}